TriApex Laboratories Co., Ltd.: China’s Largest CRO for Cardiovascular and Metabolic Preclinical Research Refiles for HKEX Listing
NewTimeSpace News: TriApex Laboratories Co., Ltd. refiled its listing application with the Hong Kong Stock Exchange on June 15, with Citi and Haitong International acting as joint sponsors. Founded in 2008, the company is an innovative Contract Research Organization (CRO) providing integrated disease biology-based solutions to global pharmaceutical firms and research institutions. According to Frost & Sullivan, based on relevant revenue in 2025, the company ranks first among all domestic CROs specialising in preclinical research for cardiovascular and metabolic diseases.
NewTimeSpace News: TriApex Laboratories Co., Ltd. resubmitted its listing application to the Hong Kong Stock Exchange on 15 June 2026, with Citi and Haitong International serving as joint sponsors.
Established in 2008, the firm is an innovative Contract Research Organization (CRO) dedicated to delivering integrated disease biology-driven R&D solutions for global pharmaceutical companies and scientific research institutes. Moving beyond the traditional CRO role as an external vendor undertaking fragmented tasks, it has evolved into a strategic R&D partner for clients, offering comprehensive preclinical safety and efficacy studies, drug metabolism and pharmacokinetics (DMPK) research, as well as end-to-end clinical trial services spanning proof-of-concept to pivotal trials.
Focused strongly on clinical value, the company has accumulated profound expertise and extensive experience across therapeutic areas including cardiovascular and metabolic diseases, central nervous system disorders, ophthalmology, autoimmune diseases and oncology. Per data from Frost & Sullivan, measured by relevant revenue in 2025, TriApex is the largest CRO in China’s cardiovascular and metabolic preclinical research segment.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
Tags：
